Prostate Cancer Treatment and Research / Cancer Cells and Metastasis · Journal article

Induced proximity-based therapeutics for advanced prostate cancer

npj Drug Discovery. · August 14, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a narrative review summarizing recent advances in induced proximity-based therapeutic approaches targeting androgen receptor in metastatic castration-resistant prostate cancer. The source presents a mechanistic concept and state-of-the-art overview rather than original clinical or preclinical trial data, and does not provide evidence of clinical efficacy or safety.

What was studied

Journal article. Patients with metastatic castration-resistant prostate cancer (mCRPC).

Key findings

Induced proximity-based therapeutics employ event-driven pharmacology as a strategy to target AR in mCRPC These approaches are proposed as a potential mechanism to overcome resistance to androgen-deprivation and AR-targeted therapies

Safety

Induced proximity-based therapeutics employ event-driven pharmacology as a strategy to target AR in mCRPC

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a narrative review of mechanistic approaches and recent advances in a drug development strategy, without empirical trial data, clinical outcomes, or efficacy comparisons to support a clinical claim.

Caveats

Abstract does not report efficacy data, clinical outcomes, or comparative results
No sample sizes, effect sizes, confidence intervals, or p-values provided
Review of advances; does not present original clinical trial or mechanistic study results
Insufficient evidence to assess whether induced proximity approaches are superior to existing therapies

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Source is a review article; no primary study design present.

Directness

limited

Discusses therapeutic concepts and mechanisms without clinical endpoint data.

Consistency

insufficient

No synthesis of multiple studies or comparison of findings reported.

Risk of bias

insufficient

Review format; methodological rigour and bias assessment not applicable.

Sample adequacy

insufficient

No empirical data or patient cohort presented in abstract.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Abstract Metastatic castration-resistant prostate cancers (mCRPC) remain dependent on androgen receptor (AR) signaling despite resistance to androgen-deprivation and AR-targeted therapies. Induced proximity-based therapeutics employ event-driven pharmacology to target AR, potentially overcoming resistance mechanisms. Herein, we highlight recent advances in induced proximity strategies targeting AR in mCRPC.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Prostate Cancer Treatment and ResearchCancer Cells and MetastasisWilliam D. FiggJohn ChingCindy H. Chau